Definium Therapeutics, Inc. (DFTX) Stock Analysis

Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results

Tue, September 8, 2026 at 11:00 AM UTC 2 min read

Definium Therapeutics has been granted Breakthrough Therapy Designation for its DT120 (lysergide) Orally Disintegrating Tablet (ODT) in the treatment of Major Depressive Disorder (MDD) after positive Phase 3 trial results. This designation can expedite the development and review process, potentially leading to a faster market entry. For investors, this news highlights the company's innovative approach to addressing a significant mental health issue, potentially increasing its market value and attractiveness in the pharmaceutical sector.

Read full article →

DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’

Wed, August 12, 2026 at 5:06 PM UTC 3 min read

DFTX stock surged following positive trial results for its psychedelic drug, DT120, which showed promise in treating anxiety. This development has sparked investor enthusiasm, with many believing that DT120 could significantly disrupt the mental health market. The encouraging data may position DFTX favorably for future growth and potential partnerships, making it a stock to watch for investors interested in innovative healthcare solutions.

Read full article →